Coverart for item
The Resource Camptothecins in cancer therapy, edited by Val R. Adams and Thomas G. Burke, (electronic book)

Camptothecins in cancer therapy, edited by Val R. Adams and Thomas G. Burke, (electronic book)

Label
Camptothecins in cancer therapy
Title
Camptothecins in cancer therapy
Statement of responsibility
edited by Val R. Adams and Thomas G. Burke
Contributor
Subject
Language
eng
Summary
This is a critical review of our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer p
Member of
Cataloging source
GW5XE
Dewey number
616.99/4061
Illustrations
illustrations
Index
index present
LC call number
RC271.C35
LC item number
C345 2005
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
http://library.link/vocab/relatedWorkOrContributorName
  • Burke, Thomas G.
  • Adams, Val R
Series statement
Cancer drug discovery and development
http://library.link/vocab/subjectName
  • Camptothecin
  • Cancer
  • Camptothecin
  • Neoplasms
  • Antineoplastic Agents, Phytogenic
  • Camptothecin
  • Camptothecin
  • Medicine
  • MEDICAL
  • HEALTH & FITNESS
Label
Camptothecins in cancer therapy, edited by Val R. Adams and Thomas G. Burke, (electronic book)
Instantiates
Publication
Bibliography note
Includes bibliographical references and index
Color
multicolored
Contents
Mechanism of action of topoisomerase I poisons / Leroy F. Liu and Shyamal D. Desai -- Crystallographic insight into the mechanism of drug-induced topoisomerase I DNA damage / Alex B. Burgin, Jr., Bart L. Staker, and Lance Stewart -- Inhibitors of topoisomerase I function / Sidney M. Hecht -- Cytotoxic mechanisms of the topoisomerase I inhibitors / Yves Pommier ... [et al.] -- Biochemical and genetic analyses of DNA topoisomerase I-mediated DNA damage / Robert C.A.M. Van Waardenburg and Mary-Ann Bjornsti -- Preclinical models for evaluating topoisomerase-I targeted drugs / Aarti S. Juvekar ... [et al.] -- Mechanisms of resistance to camptothecins / Zeshaan A. Rasheed and Eric H. Rubin -- Recent advances in camptothecin drug design and delivery strategies / Thomas G. Burke ... [et al.] -- Clinical experience with 9-aminocamptothecin: lessons for new drug development / Chris H. Takimoto -- Clinical studies of rubitecan (9-nitro 20(s) camptothecin) / Hilary Hewes, Judith A. Smith, and Claire Verschraegen -- Irinotecan: current clinical status and pharmacological aspects / Laurent P. Rivory -- Clinical experience with topotecan / Aimee K. Bence and Val R. Adams -- The clinical development of lurtotecan: experience with water-soluble and liposomal forms / Keith T. Flaherty ... [et al.] -- Preclinical and clinical development of dx-8951f (exatecan mesylate): a hexacyclic camptothecin analog / Eric K. Rowinsky -- Camptothecins in the treatment of primary brain tumors / Clinton F. Stewart, Markos Leggas, and Henry S. Friedman -- Camptothecins in the treatment of lung cancer / Pankaj Kumar ... [et al.] -- Use of camptothecins in the treatment of leukemia and related disorders / Bejamin M.F. Mow and Scott H. Kaufmann
Control code
SPR655853893
Dimensions
unknown
Extent
1 online resource (xiii, 460 p.)
Form of item
online
Isbn
9781592598663
Other physical details
ill. (some col.)
Specific material designation
remote
Label
Camptothecins in cancer therapy, edited by Val R. Adams and Thomas G. Burke, (electronic book)
Publication
Bibliography note
Includes bibliographical references and index
Color
multicolored
Contents
Mechanism of action of topoisomerase I poisons / Leroy F. Liu and Shyamal D. Desai -- Crystallographic insight into the mechanism of drug-induced topoisomerase I DNA damage / Alex B. Burgin, Jr., Bart L. Staker, and Lance Stewart -- Inhibitors of topoisomerase I function / Sidney M. Hecht -- Cytotoxic mechanisms of the topoisomerase I inhibitors / Yves Pommier ... [et al.] -- Biochemical and genetic analyses of DNA topoisomerase I-mediated DNA damage / Robert C.A.M. Van Waardenburg and Mary-Ann Bjornsti -- Preclinical models for evaluating topoisomerase-I targeted drugs / Aarti S. Juvekar ... [et al.] -- Mechanisms of resistance to camptothecins / Zeshaan A. Rasheed and Eric H. Rubin -- Recent advances in camptothecin drug design and delivery strategies / Thomas G. Burke ... [et al.] -- Clinical experience with 9-aminocamptothecin: lessons for new drug development / Chris H. Takimoto -- Clinical studies of rubitecan (9-nitro 20(s) camptothecin) / Hilary Hewes, Judith A. Smith, and Claire Verschraegen -- Irinotecan: current clinical status and pharmacological aspects / Laurent P. Rivory -- Clinical experience with topotecan / Aimee K. Bence and Val R. Adams -- The clinical development of lurtotecan: experience with water-soluble and liposomal forms / Keith T. Flaherty ... [et al.] -- Preclinical and clinical development of dx-8951f (exatecan mesylate): a hexacyclic camptothecin analog / Eric K. Rowinsky -- Camptothecins in the treatment of primary brain tumors / Clinton F. Stewart, Markos Leggas, and Henry S. Friedman -- Camptothecins in the treatment of lung cancer / Pankaj Kumar ... [et al.] -- Use of camptothecins in the treatment of leukemia and related disorders / Bejamin M.F. Mow and Scott H. Kaufmann
Control code
SPR655853893
Dimensions
unknown
Extent
1 online resource (xiii, 460 p.)
Form of item
online
Isbn
9781592598663
Other physical details
ill. (some col.)
Specific material designation
remote

Library Locations

Processing Feedback ...